Amylase Testing Market

Amylase Testing Market Overview

The global amylase testing market was valued at around US$ 587.1 Million at the end of 2021. The market is projected to register a 3.1% CAGR and top a valuation of US$ 830.2 Million by 2032.

Amylase testing demand is being driven by an increase in pancreatic diseases such as acute pancreatitis, alcohol related pancreatitis, cholecystitis, and others in the general population.

The amylase test, also known as the "amy test," "serum amylase," or "urine amylase test," is a diagnostic procedure used to assess the amount of amylase in the blood and urine. Our body naturally produces amylase, an enzyme that facilitates the breakdown of complex carbohydrates like starch. Our salivary glands and pancreas are where most of our amylase is found as "salivary amylase" and "pancreatic amylase," respectively.

An amylase test is mostly used to evaluate pancreatic health. Amylase levels that are abnormal in the blood and urine point to a problem with the pancreas or an infection. The test results can assist the doctor in diagnosing the problem and recommending additional care.

The blood's normal amylase level should range from 30 to 110 units per litre (U/L). The pancreas may be in risk if there is any variation from the normal range.

Tumours, gall bladder infections, and kidney failure can cause hyperamylasaemia.

Attributes	Details
Amylase Testing Market Value in 2021	US$ 587.1 Million
Amylase Testing Market Value in 2032	US$ 830.2 Million
Amylase Testing Market CAGR (2022 to 2032)	3.1%

What are the Major Drivers Boosting the Demand for Amylase Testing Market?

The market for amylase testing is anticipated to develop as a result of growing use of amylase testing for accurate assessment of pancreatic and salivary gland function.

The market is expanding due to the efficiency with which amylase testing is able to diagnose conditions like acute, chronic, or alcoholic pancreatitis, ruptured ectopic pregnancies, digestive problems (such perforated peptic ulcers, appendicitis, salivary gland infections, or tumours), and more.

Amylase testing market expansion is anticipated to be aided by the simplicity of using blood or urine samples for the test. Additionally, increasing chronic conditions such as pancreatitis which is more common in smokers is increasing day by day which is supposed to boost the market growth over the forecast period. For instance, according to BMC gastroenterology article published in August 2021, around 2,814,973 cases of acute pancreatitis worldwide were founded in 2019, in which the smoking was considered as the key risk factor.

Furthermore, the market for amylase testing is growing as a result of the chemicals and equipment needed for testing amylase being widely accessible.

Moreover, the market for amylase testing is driven due to the expansion of regional manufacturers, particularly in areas like East Asia, South Asia, and the GCC nations. These manufacturers make products that are more affordable and are therefore more readily available, which increases product adoption.

Which Region Shows Strong Growth Potential in the Amylase Testing Market?

The amylase testing market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America dominated the regional amylase testing market in terms of revenue, due to greater product utilization in the region. Additionally, growing geriatric population with increasing prevalence of pancreatic cancer in them is supposed to drive the regional market. For instance, in 2022, according to American Cancer Society about 62,210 patients were diagnosed with pancreatic cancer, in which around 49,830 died due to it.

Additionally, it also states in U.S, the pancreatic cancer accounts for about 3% of all cancer and about 7% of death occurs due to pancreatic cancer.

Moreover, in Latin America the market is supposed to steadily increase over the coming years due to region's expanding product availability.

Moreover, Europe is anticipated to be the second most lucrative region due to the greater product acceptance in the region.

Who are the Key Manufacturers in the Amylase Testing Market?

Amano Enzyme, Novozymes, DSM, BASF, Advanced Enzyme Tech., Suzhou Sino Enzymes, Shenzhen Leveking Bio-Engineering, Chemzyme Biotechnology, Enmex, and Biolaxi

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 3.1% 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Million, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Sample Type End-Use Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Argentina Germany United Kingdom France Spain Italy China Japan South Korea India Thailand Malaysia Indonesia Australia New Zealand GCC South Africa North Africa Turkey
Key Players	Amano Enzyme Novozymes DSM BASF Advanced Enzyme Tech. Suzhou Sino Enzymes Shenzhen Leveking Bio-Engineering Chemzyme Biotechnology Enmex Biolaxi
Customization	Available Upon Request

Key Segments Covered in the Amylase Testing Market Survey

By Sample Type:

• Blood Sample
• Urine Sample

By End-use:

• Diagnostic Laboratories
• Hospitals
• Speciality Clinics

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)